Does Medicare Cap Insulin at $35 in 2026? (Part D and Part B Rules)

Direct Answer: Does Medicare Cap Insulin at $35 in 2026?

Yes. Medicare caps insulin cost sharing at $35 for a month's supply in 2026, with no deductible. The cap applies to insulin covered under Medicare Part D (pharmacy-dispensed) and Medicare Part B (used in a covered insulin pump). Standalone Part D plans and Medicare Advantage drug plans (MA-PD) must apply the same $35 cap. The cap does not apply to commercial insurance, hospital inpatient billing, or non-insulin diabetes drugs.

How the $35 Cap Works Under Medicare Part D in 2026

Medicare Part D sets the insulin cap at $35 for a one-month supply of each covered insulin product, and the cap has applied since January 1, 2023 under the Inflation Reduction Act (P.L. 117-169, signed August 16, 2022). No deductible applies to insulin under Part D, so the $35 ceiling holds in the deductible phase, the initial coverage phase, and the catastrophic phase alike. A two-month supply cannot exceed $70, and a three-month mail-order supply cannot exceed $105.

For 2026, the Part D insulin formula has one added wrinkle from the law's later phase-in: a beneficiary pays the lesser of $35, 25 percent of the negotiated price, or 25 percent of the Maximum Fair Price if that specific insulin has been selected for Medicare drug-price negotiation. In practice most beneficiaries still pay exactly $35, because few insulins have been selected for negotiation so far, but it means the true 2026 ceiling can land slightly below $35 for a negotiated product. The cap is also per insulin product, so a beneficiary using two different insulins, such as a basal and a rapid-acting formulation, pays up to $35 for each rather than $35 total.

How the $35 Cap Works Under Medicare Part B (Insulin Pumps) in 2026

Medicare Part B covers insulin only when it is delivered through a covered insulin pump classified as durable medical equipment (DME), and that coverage carries its own $35 cap effective July 1, 2023. Unlike most other Part B-covered drugs and supplies, the 2026 Part B deductible of $283 does not apply to the insulin itself, only to the pump hardware and tubing. A beneficiary pays no more than $35 for a month's supply of pump insulin, and no more than $70 for a two-month supply.

Part B insulin coverage is narrow by design. It covers insulin used in a traditional tubed insulin pump billed as DME, but it does not cover insulin delivered by disposable patch pumps, insulin pens, or syringes, and it does not extend the $35 rate to pump supplies such as infusion sets, reservoirs, or batteries; those items keep standard Part B cost sharing. Anyone who injects insulin outside a Part B-covered pump needs a Medicare Part D plan to get the $35 cap on that insulin.

What the $35 Insulin Cap Does Not Cover

Three categories fall outside the $35 Medicare insulin cap. Non-insulin diabetes medications, including GLP-1 agonists such as semaglutide (Ozempic) and tirzepatide (Mounjaro), are not insulin, so the cap does not touch their cost sharing even though they treat the same condition. Insulin administered during a hospital inpatient stay is billed under Medicare Part A as part of the facility charge, not under Part D or Part B, so the $35 monthly cap has no bearing on inpatient insulin costs. Commercial employer plans, ACA Marketplace plans, and Medicaid managed care plans outside Medicare are not bound by this federal cap; commercial insulin costs are instead governed by individual state copay-cap laws where they exist.

Medicare Advantage and the $35 Insulin Cap

Medicare Advantage plans that bundle Part D drug coverage, known as MA-PD plans, must apply the identical $35 monthly cap and zero-deductible rule to covered insulins as standalone Part D plans; the Inflation Reduction Act's insulin provisions attach to the Part D benefit itself, regardless of which type of plan delivers it. Some MA-PD plans go beyond the federal floor and offer $0 cost sharing for insulin as a supplemental benefit, so it is worth comparing plan Evidence of Coverage documents during the Annual Enrollment Period (October 15 to December 7, 2026) rather than assuming every plan simply charges the full $35.

What Insulin Cost Before the $35 Cap (Pre-2023 Rules)

Before January 1, 2023, Medicare Part D beneficiaries paid standard cost sharing for insulin, which meant full retail price during the deductible phase (historically $300 to $500 per vial for branded analog insulin), 25 percent coinsurance in the initial coverage phase, and additional cost sharing in the coverage gap. A beneficiary who started a new Part D plan in January could pay several hundred dollars out of pocket for insulin before the plan's cost sharing kicked in. The Inflation Reduction Act eliminated that deductible exposure entirely for insulin and replaced the variable coinsurance with a flat $35 ceiling, a change CMS estimates saves the average insulin-using Part D enrollee several hundred dollars a year.

How to Confirm Your Medicare Plan Is Applying the $35 Cap Correctly

Check a recent pharmacy receipt or Part D Explanation of Benefits for any insulin fill in 2026; the amount billed to you should never exceed $35 for a one-month supply, and no deductible line should appear next to an insulin charge. If a pharmacy or plan charged more, call the member services number on the back of your Medicare card, cite the Inflation Reduction Act's insulin cost-sharing cap, and ask for a billing correction and refund. The Medicare Plan Finder at medicare.gov/plan-compare lets you enter your specific insulin brands before the Annual Enrollment Period to confirm which Part D and Medicare Advantage plans cover them on their 2026 formulary.

Does Medicare Part D really cap insulin at $35 with no deductible in 2026?

Yes. Every standalone Part D plan and every Medicare Advantage drug plan (MA-PD) must charge no more than $35 for a one-month supply of each covered insulin product in 2026, and no deductible applies to insulin at any point in the plan year. This rule comes from the Inflation Reduction Act (P.L. 117-169) and took effect January 1, 2023.

Does the $35 cap apply to insulin used in an insulin pump under Part B?

Yes. Since July 1, 2023, Medicare Part B caps insulin delivered through a covered insulin pump at $35 for a month's supply, and the 2026 Part B deductible of $283 does not apply to that insulin. The cap covers only the insulin itself; the pump hardware and tubing still carry standard Part B cost sharing.

Does Medicare Advantage cap insulin at $35 too?

Yes. Any Medicare Advantage plan that includes Part D drug coverage (an MA-PD plan) must apply the same $35 monthly cap and no-deductible rule as standalone Part D plans. Some MA-PD plans offer $0 insulin as an enhanced benefit, so it is worth checking your plan's 2026 Evidence of Coverage.

What happened to the insulin cap before 2023?

Before January 1, 2023, Medicare Part D beneficiaries paid full retail price for insulin during the deductible phase, historically $300 to $500 per vial for branded analog insulin, followed by 25 percent coinsurance and coverage-gap cost sharing. The Inflation Reduction Act replaced that variable structure with the flat $35 cap and eliminated the deductible for insulin entirely.

Does the $35 cap cover Ozempic or other diabetes drugs that aren't insulin?

No. GLP-1 agonists such as semaglutide (Ozempic) and tirzepatide (Mounjaro) are not insulin, so the $35 insulin cap does not apply to them even though they treat diabetes. Their cost sharing depends on your Part D plan's formulary tier for that specific drug.

Can I be charged more than $35 if I use two different insulins?

Yes, because the cap is per insulin product, not per person. If you use a basal insulin and a rapid-acting insulin, each one carries its own $35 monthly ceiling, so your combined insulin cost could be up to $70 a month rather than $35 total.

What should I do if my pharmacy charges me more than $35 for insulin?

Call the member services number on your Medicare card or your Part D plan's customer service line and cite the Inflation Reduction Act's $35 insulin cost-sharing cap. Ask for a billing correction and a refund of any amount charged above $35, including any deductible that was applied to the insulin in error.

Does the $35 insulin cap apply outside Medicare, like on my employer's health plan?

No. The $35 cap is a Medicare-specific federal rule and does not apply to commercial employer plans, ACA Marketplace plans, or Medicaid managed care outside Medicare. Over 30 states have passed their own insulin copay-cap laws for state-regulated commercial plans, and several insulin manufacturers offer $35-per-month savings programs for non-Medicare patients.